Rabbit Monoclonal ERK1 phospho T202 + Y204 antibody. Suitable for WB, ICC and reacts with Human, Mouse, Rat samples.
IgG
Rabbit
pH: 7.2 - 7.4
Preservative: 0.01% Sodium azide
Constituents: 59% PBS, 40% Glycerol (glycerin, glycerine), 0.05% BSA
Liquid
Monoclonal
WB | ICC | |
---|---|---|
Human | Tested | Tested |
Mouse | Tested | Tested |
Rat | Tested | Tested |
Species | Dilution info | Notes |
---|---|---|
Species Human | Dilution info 1/1000 | Notes - |
Species Mouse | Dilution info 1/1000 | Notes - |
Species Rat | Dilution info 1/1000 | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Human | Dilution info 5 µg/mL | Notes - |
Species Mouse | Dilution info 5 µg/mL | Notes - |
Species Rat | Dilution info 5 µg/mL | Notes - |
Serine/threonine kinase which acts as an essential component of the MAP kinase signal transduction pathway (PubMed:34497368). MAPK1/ERK2 and MAPK3/ERK1 are the 2 MAPKs which play an important role in the MAPK/ERK cascade. They participate also in a signaling cascade initiated by activated KIT and KITLG/SCF. Depending on the cellular context, the MAPK/ERK cascade mediates diverse biological functions such as cell growth, adhesion, survival and differentiation through the regulation of transcription, translation, cytoskeletal rearrangements. The MAPK/ERK cascade also plays a role in initiation and regulation of meiosis, mitosis, and postmitotic functions in differentiated cells by phosphorylating a number of transcription factors. About 160 substrates have already been discovered for ERKs. Many of these substrates are localized in the nucleus, and seem to participate in the regulation of transcription upon stimulation. However, other substrates are found in the cytosol as well as in other cellular organelles, and those are responsible for processes such as translation, mitosis and apoptosis. Moreover, the MAPK/ERK cascade is also involved in the regulation of the endosomal dynamics, including lysosome processing and endosome cycling through the perinuclear recycling compartment (PNRC); as well as in the fragmentation of the Golgi apparatus during mitosis. The substrates include transcription factors (such as ATF2, BCL6, ELK1, ERF, FOS, HSF4 or SPZ1), cytoskeletal elements (such as CANX, CTTN, GJA1, MAP2, MAPT, PXN, SORBS3 or STMN1), regulators of apoptosis (such as BAD, BTG2, CASP9, DAPK1, IER3, MCL1 or PPARG), regulators of translation (such as EIF4EBP1) and a variety of other signaling-related molecules (like ARHGEF2, DEPTOR, FRS2 or GRB10) (PubMed:35216969). Protein kinases (such as RAF1, RPS6KA1/RSK1, RPS6KA3/RSK2, RPS6KA2/RSK3, RPS6KA6/RSK4, SYK, MKNK1/MNK1, MKNK2/MNK2, RPS6KA5/MSK1, RPS6KA4/MSK2, MAPKAPK3 or MAPKAPK5) and phosphatases (such as DUSP1, DUSP4, DUSP6 or DUSP16) are other substrates which enable the propagation the MAPK/ERK signal to additional cytosolic and nuclear targets, thereby extending the specificity of the cascade.
Mitogen-activated protein kinase 1 phospho T185 + Y187, Mapk3 phospho T202 + Y204, Mapk3 phospho T202 + Y204, Mitogen-activated protein kinase 1 phospho T202 + Y204, Mitogen-activated protein kinase 1 phospho T202 + Y204, Mitogen-activated protein kinase 1 phospho T202 + Y204
ERK1, PRKM3, PRKM3, ERK1, MAPK3, Mitogen-activated protein kinase 3, MAP kinase 3, MAPK 3, ERT2, Extracellular signal-regulated kinase 1, Insulin-stimulated MAP2 kinase, MAP kinase isoform p44, Microtubule-associated protein 2 kinase, p44-ERK1, ERK-1, p44-MAPK
Rabbit Monoclonal ERK1 phospho T202 + Y204 antibody. Suitable for WB, ICC and reacts with Human, Mouse, Rat samples.
IgG
Rabbit
pH: 7.2 - 7.4
Preservative: 0.01% Sodium azide
Constituents: 59% PBS, 40% Glycerol (glycerin, glycerine), 0.05% BSA
Liquid
Monoclonal
EPR25015-F2
Affinity purification Protein A
kappa
Blue Ice
1-2 weeks
+4°C
-20°C
Upon delivery aliquot
Avoid freeze / thaw cycle
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
This product is a recombinant monoclonal antibody, which offers several advantages including:
For more information, read more on recombinant antibodies.
This supplementary information is collated from multiple sources and compiled automatically.
ERK1 and ERK2 also known as p44 and p42 MAPK respectively are important proteins in the MAP kinase signaling pathway. They are expressed in various tissues with significant presence in the brain lungs and skin. ERK1 has a molecular weight of approximately 44 kDa while ERK2 has a molecular weight of around 42 kDa. Both proteins become activated through phosphorylation which is essential for their function in cellular processes.
ERK1 and ERK2 serve as key players in cellular growth differentiation and survival. They form part of a complex cascade where they transduce signals from the cell membrane to the nucleus after activation by phosphorylation. This phosphorylation enables them to modify various downstream targets involved in regulating gene expression and cellular response to external stimuli.
ERK1 and ERK2 are critical components of the MAPK/ERK pathway and the Ras-Raf-MEK-ERK signaling cascade. These pathways regulate a multitude of cellular activities including proliferation and differentiation. In the MAPK/ERK pathway proteins like Ras and Raf serve as upstream activators of ERK1 and ERK2. Both ERK1 and ERK2 also interact with other signaling proteins such as MEK1/2 which directly phosphorylates and activates them.
Dysregulation of ERK1 and ERK2 is associated with various pathologies including cancer and neurodegenerative diseases. Abnormal activation of these proteins often leads to uncontrolled cell proliferation contributing to oncogenesis. For instance mutations in proteins like Ras which regulate ERK1 and ERK2 can result in continuous activation and lead to tumor formation. Furthermore altered ERK1 and ERK2 signaling is linked to neurodegeneration impacting neuronal survival and function.
We have tested this species and application combination and it works. It is covered by our product promise.
We have not tested this specific species and application combination in-house, but expect it will work. It is covered by our product promise.
This species and application combination has not been tested, but we predict it will work based on strong homology. However, this combination is not covered by our product promise.
We do not recommend this combination. It is not covered by our product promise.
We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.
In the unlikely event of one of our products not working as expected, you are covered by our product promise.
Full details and terms and conditions can be found here:
Terms & Conditions.
ab288063 staining ERK1 (phospho T202 + Y204) + ERK2 (phospho T185 + Y187) in untreated, PMA treated and PMA + LP treated A-10 cells. The cells were fixed with 100% Methanol (5 min), permeabilized with 0.1% PBS-Triton X-100 for 5 minutes and then blocked with 1% BSA/10% normal goat serum/0.3M glycine in 0.1%PBS-Tween for 1h. The cells were then incubated overnight at 4°C with ab288063 at 5µg/ml and Anti-alpha Tubulin antibody [DM1A] - Loading Control ab7291, Mouse monoclonal [DM1A] to alpha Tubulin - Loading Control. Cells were then incubated with Goat Anti-Rabbit IgG H&L (Alexa Fluor® 488) preadsorbed ab150081, Goat polyclonal Secondary Antibody to Rabbit IgG - H&L (Alexa Fluor® 488), pre-adsorbed at 1/1000 dilution (shown in green) and Goat Anti-Mouse IgG H&L (Alexa Fluor® 594) preadsorbed ab150120, Goat polyclonal Secondary Antibody to Mouse IgG - H&L (Alexa Fluor® 594), pre-adsorbed at 1/1000 dilution (shown in pseudocolour magenta). Nuclear DNA was labelled with DAPI (shown in blue).
Image was acquired with a high-content analyser (Operetta CLS, Perkin Elmer) and a maximum intensity projection of confocal sections is shown.
The image shows increased nuclear staining after 24hr serum starvation followed by treatment with PMA (200nM, 15min) of A-10 cells. The Lambda Phoshatase treatment then removes all staining of antibody with no phospho ERK1/2 remaining.
ab288063 staining ERK1 (phospho T202 + Y204) + ERK2 (phospho T185 + Y187) in untreated, PMA treated and PMA + LP treated NIH/3T3 cells. The cells were fixed with 100% Methanol (5 min), permeabilized with 0.1% PBS-Triton X-100 for 5 minutes and then blocked with 1% BSA/10% normal goat serum/0.3M glycine in 0.1%PBS-Tween for 1h. The cells were then incubated overnight at 4°C with ab288063 at 5µg/ml and Anti-alpha Tubulin antibody [DM1A] - Loading Control ab7291, Mouse monoclonal [DM1A] to alpha Tubulin - Loading Control. Cells were then incubated with Goat Anti-Rabbit IgG H&L (Alexa Fluor® 488) preadsorbed ab150081, Goat polyclonal Secondary Antibody to Rabbit IgG - H&L (Alexa Fluor® 488), pre-adsorbed at 1/1000 dilution (shown in green) and Goat Anti-Mouse IgG H&L (Alexa Fluor® 594) preadsorbed ab150120, Goat polyclonal Secondary Antibody to Mouse IgG - H&L (Alexa Fluor® 594), pre-adsorbed at 1/1000 dilution (shown in pseudocolour magenta). Nuclear DNA was labelled with DAPI (shown in blue).
Image was acquired with a high-content analyser (Operetta CLS, Perkin Elmer) and a maximum intensity projection of confocal sections is shown.
Also suitable in cells fixed with 4% paraformaldehyde (10 min).
The image shows increased nuclear staining after 24hr serum starvation followed by treatment with PMA (200nM, 15min) of NIH/3T3 cells. The Lambda Phoshatase treatment then removes all staining of antibody with no phospho ERK1/2 remaining.
Anti-ERK1 + ERK2 antibody [EPR17526] ab184699 was used as a Pan ERK1 + ERK2 control for ab288063. The results showed nuclear staining on untreated, with no increase after PMA treatment and no reduction after PMA + LP treated in NIH/3T3 cells.
ab288063 staining ERK1 (phospho T202 + Y204) + ERK2 (phospho T185 + Y187) in untreated, PMA treated and PMA + LP treated HeLa cells. The cells were fixed with 100% Methanol (5 min), permeabilized with 0.1% PBS-Triton X-100 for 5 minutes and then blocked with 1% BSA/10% normal goat serum/0.3M glycine in 0.1%PBS-Tween for 1h. The cells were then incubated overnight at 4°C with ab288063 at 5µg/ml and Anti-alpha Tubulin antibody [DM1A] - Loading Control ab7291, Mouse monoclonal [DM1A] to alpha Tubulin - Loading Control. Cells were then incubated with Goat Anti-Rabbit IgG H&L (Alexa Fluor® 488) preadsorbed ab150081, Goat polyclonal Secondary Antibody to Rabbit IgG - H&L (Alexa Fluor® 488), pre-adsorbed at 1/1000 dilution (shown in green) and Goat Anti-Mouse IgG H&L (Alexa Fluor® 594) preadsorbed ab150120, Goat polyclonal Secondary Antibody to Mouse IgG - H&L (Alexa Fluor® 594), pre-adsorbed at 1/1000 dilution (shown in pseudocolour magenta). Nuclear DNA was labelled with DAPI (shown in blue).
Image was acquired with a high-content analyser (Operetta CLS, Perkin Elmer) and a maximum intensity projection of confocal sections is shown.
The image shows increased nuclear staining after 24hr serum starvation followed by treatment with PMA (200nM, 15min) of HeLa cells. The Lambda Phoshatase treatment then removes all staining of antibody with no phospho ERK1/2 remaining.
Anti-ERK1 + ERK2 antibody [EPR17526] ab184699 was used as a Pan ERK1 + ERK2 control for ab288063. The results showed nuclear staining on untreated, with no increase after PMA treatment and no reduction after PMA + LP treated in HeLa cells.
ab288063 was shown to specifically react with ERK1/2 (pT202+ Y204). The signal was significantly reduced after treat with 10 uM U0126.
Samples were run on an SDS-PAGE gel then transferred onto a nitrocellulose membrane. Membranes were blocked in 5% BSA in TBS-0.1 % Tween® 20 (TBS-T).
ab288063, Anti-ERK1 + ERK2 antibody [EPR17526] ab184699 and Anti-Tubulin antibody [DM1A] - Loading Control (Anti-alpha Tubulin antibody [DM1A] - Loading Control ab7291) were incubated overnight at 4°C at 1/1000, 1/10000 and 1/5000 dilutions, respectively.
Blots were developed with Goat anti-Rabbit IgG H&L 800CW and Goat anti-Mouse IgG H&L 680RD secondary antibodies at 1/20000 dilution for 1 hour at room temperature before imaging.
All lanes: Western blot - Anti-ERK1 (phospho T202+Y204) + ERK2 (phospho T185+Y187) antibody [EPR25015-F2] (ab288063) at 1/1000 dilution
Lane 1: HeLa cells, serum-starved overnight, treated with U0126 (10 uM, 60 min) at 20 µg
Lane 2: HeLa cells, serum-starved overnight, treated with TPA (200 nM, 15 min) at 20 µg
Lane 3: NIH3T3 cells, serum-starved overnight, treated with U0126 (10 uM, 60 min) at 20 µg
Lane 4: NIH3T3 cells, serum-starved overnight, treated with TPA (200 nM, 15 min) at 20 µg
Lane 5: A10 cells, serum-starved overnight, treated with U0126 (10 uM, 60 min) at 20 µg
Lane 6: A10 cells, serum-starved overnight, treated with TPA (200 nM, 15 min) at 20 µg
Lanes 1 - 6: Goat anti-Rabbit IgG H&L 800CW at 1/20000 dilution
Lanes 1 - 6: Goat anti-Mouse IgG H&L 680RD at 1/20000 dilution
Performed under reducing conditions.
Observed band size: 42 kDa, 44 kDa, 50 kDa
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com